Akebia Therapeutics

(NASDAQ) AKBA

Current Price$1.40

Market Cap$369.67M

Since IPO (2014)-95%

5 Year-57%

1 Year-43%

1 Month-1%

Akebia Therapeutics Financials at a Glance

Market Cap

$369.67M

Revenue (TTM)

$236.19M

Net Income (TTM)

$5.34M

EPS (TTM)

$-0.02

P/E Ratio

-76.67

Dividend

$0.00

Beta (Volatility)

1.52 (High)

Dividend

$0.00

Beta (Volatility)

1.52 (High)

Price

$1.40

Volume

2,575,653.899

Open

$1.40

Price

$1.40

Volume

2,575,653.899

Open

$1.40

Previous Close

$1.40

Daily Range

$1.38 - $1.44

52-Week Range

$1.14 - $4.08

Dividend

$0.00

Beta (Volatility)

1.52 (High)

Price

$1.40

Volume

2,575,653.899

Open

$1.40

Previous Close

$1.40

Daily Range

$1.38 - $1.44

52-Week Range

$1.14 - $4.08

AKBA News

Page 1

AKBA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Akebia Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

194

CEO

John P. Butler, MBA

Website

www.akebia.com

Headquarters

Cambridge, MA 02142, US

AKBA Financials

Key Financial Metrics (TTM)

Gross Margin

83%

Operating Margin

10%

Net Income Margin

-2%

Return on Equity

Return on Capital

11%

Return on Assets

-1%

Earnings Yield

-1.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$369.67M

Shares Outstanding

267.88M

Volume

2.58M

Avg. Volume

2.98M

Financials (TTM)

Gross Profit

$196.73M

Operating Income

$23.50M

EBITDA

$21.73M

Operating Cash Flow

$67.99M

Capital Expenditure

$291.00K

Free Cash Flow

$67.99M

Cash & ST Invst.

$184.84M

Total Debt

$216.30M

Akebia Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$57.62M

+23.9%

Gross Profit

$45.41M

+73.8%

Gross Margin

78.80%

N/A

Market Cap

$369.67M

N/A

Market Cap/Employee

$2.04M

N/A

Employees

181

N/A

Net Income

$12.24M

+46.3%

EBITDA

$6.09M

+7.5%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$31.45M

+77.0%

Accounts Receivable

$47.03M

+36.8%

Inventory

$0.00

-100.0%

Long Term Debt

$176.21M

-1.6%

Short Term Debt

$43.63M

+349.2%

Return on Assets

-1.42%

N/A

Return on Invested Capital

11.00%

N/A

Free Cash Flow

$30.97M

+793.1%

Operating Cash Flow

$31.13M

+797.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

FDMT4D Molecular Therapeutics, Inc.

FDMT4D Molecular Therapeutics, Inc.$9.09+2.48%

CMPXCompass Therapeutics, Inc.

CMPXCompass Therapeutics, Inc.$1.96+10.73%

RIGLRigel Pharmaceuticals, Inc.

RIGLRigel Pharmaceuticals, Inc.$29.40+1.73%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$10.64-3.80%

ZVRAZevra Therapeutics, Inc.

ZVRAZevra Therapeutics, Inc.$10.07-0.98%

GOSSGossamer Bio, Inc.

GOSSGossamer Bio, Inc.$0.37+0.54%

VTYXVentyx Biosciences, Inc.

VTYXVentyx Biosciences, Inc.$14.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$50.22-0.03%

RIVNRivian Automotive

RIVNRivian Automotive$15.02-0.08%

FFord Motor Company

FFord Motor Company$11.88-0.02%

Questions About AKBA

What is the current price of Akebia Therapeutics?

Akebia Therapeutics is trading at $1.40 per share.

What is the 52-week range for Akebia Therapeutics?

Over the past 52 weeks, Akebia Therapeutics has traded between $1.14 and $4.08.

How much debt does Akebia Therapeutics have?

As of the most recent reporting period, Akebia Therapeutics reported total debt of $216.30M.

How much cash does Akebia Therapeutics have on hand?

Akebia Therapeutics reported $186.54M in cash and cash equivalents in its most recent financial results.

What is Akebia Therapeutics’s dividend yield?

Akebia Therapeutics does not currently have a dividend yield.

Akebia Therapeutics

Akebia Therapeutics Financials at a Glance

AKBA News

Akebia (AKBA) Q2 Revenue Jumps 43%

Why Shares of Akebia Therapeutics Were Up Tuesday

Why Akebia Therapeutics Stock Is Soaring Today

Why Akebia Therapeutics Stock Is Plunging Today

Why Akebia Therapeutics Stock Is Crashing Today

Why Akebia Therapeutics Stock Is Crushing It Today

2 Small-Cap Stocks That Could Double Your Money

Why Akebia Therapeutics Stock Sank Today

AKBA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Akebia Therapeutics

AKBA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Akebia Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AKBA

What is the current price of Akebia Therapeutics?

What is the 52-week range for Akebia Therapeutics?

How much debt does Akebia Therapeutics have?

How much cash does Akebia Therapeutics have on hand?

What is Akebia Therapeutics’s dividend yield?

Premium Investing Services